NCT02024945View on ClinicalTrials.gov

Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome

CompletedOBSERVATIONAL
Enrollment

437

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

Propiverine

Propiverine 15 mg tablets or 30 mg regulated release capsules

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY